Claims for Patent: 10,240,124

Summary for Patent: 10,240,124

Title:	Cell culture substrate comprising a laminin and a cadherin
Abstract:	The present disclosure related to isolated laminin-521, methods for making recombinant laminin-521, host cells that express recombinant laminin-521, and compositions containing laminin-521. Laminin-521 can maintain stem cells in vitro pluripotency, enable self-renewal, and enable single cell survival of human embryonic stem cells. When pluripotent human embryonic stem cells are cultured on plates coated with recombinant laminin-521 (laminin-11), in the absence of differentiation inhibitors or feeder cells, the embryonic stem cells proliferate and maintain their pluripotency. It has also been discovered that human recombinant laminin-521 (laminin-11) provides single cell survival of stem cells after complete dissociation into a single cell suspension. Useful cell culture mediums containing at most 3.9 ng/ml of beta fibroblast growth factor (bFGF) are also described herein.
Inventor(s):	Tryggvason; Karl (Djursholm, SE), Rodin; Sergey (Stockholm, SE)
Assignee:	BioLamina AB (Solna, SE)
Application Number:	14/360,040
Patent Claims:	1. A method for maintaining stem cells, comprising: plating the stem cells on a substrate comprising a laminin and a cadherin, wherein the laminin is an intact protein; and exposing the stem cells to a cell culture medium comprising at least 0.3 mM of albumin; wherein the laminin is laminin-521; wherein the cadherin is e-cadherin; and wherein the weight ratio of the laminin-521 to the e-cadherin is from 5:1 to 10:1. 2. The method of claim 1, wherein the cell culture medium is mTeSR1 medium with additional albumin to arrive at an albumin concentration of at least 0.3 mM. 3. The method of claim 1, wherein the substrate and the medium do not contain any differentiation inhibitors, feeder cells, differentiation inductors, or apoptosis inhibitors. 4. The method of claim 1, wherein the stem cells are plated at a density of 200 cells/mm.sup.2 or less. 5. The method of claim 1, wherein the stem cells are plated at a density of 200 cells/mm.sup.2 or more. 6. The method of claim 1, wherein the stem cells are plated such that no two stem cells contact each other. 7. The method of claim 1, wherein the cell culture medium is mTeSR1 medium with about 0.39 mM albumin. 8. The method of claim 1, wherein the albumin is human serum albumin. 9. The method of claim 1, wherein the human serum albumin is recombinant human serum albumin. 10. The method of claim 1, wherein the laminin is an effective recombinant laminin.

Details for Patent 10,240,124

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2031-09-22
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2031-09-22
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2031-09-22
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978		2031-09-22
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	02/17/1995		2031-09-22
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	06/11/2003		2031-09-22